Prevalence of Cefixime-Resistant Neisseria gonorrhoeae in Melbourne, Australia, 2021-2022

Eric P.F. Chow; Kerrie Stevens; Vesna De Petra; Marcus Y. Chen; Catriona S. Bradshaw; Norelle L. Sherry; Lindley A. Barbee; Lenka A. Vodstrcil; Ivette Aguirre; Kate L. Seib; Kate Maddaford; Deborah A. Williamson; Benjamin P. Howden; Christopher K. Fairley

doi:10.1093/infdis/jiae313

Prevalence of Cefixime-Resistant Neisseria gonorrhoeae in Melbourne, Australia, 2021-2022

Eric P.F. Chow^*
, Kerrie Stevens
, Vesna De Petra
, Marcus Y. Chen
, Catriona S. Bradshaw
, Norelle L. Sherry
, Lindley A. Barbee
, Lenka A. Vodstrcil
, Ivette Aguirre
, Kate L. Seib
, Kate Maddaford
, Deborah A. Williamson
, Benjamin P. Howden
, Christopher K. Fairley

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

Abstract

While ceftriaxone remains the first-line treatment for gonorrhea, the US Centers for Disease Control and Prevention recommended cefixime as a second-line treatment in 2021. We tested 1176 Neisseria gonorrhoeae isolates among clients attending the Melbourne Sexual Health Centre in 2021 and 2022. The prevalence of cefixime resistance was 6.3% (74/1176), azithromycin resistance was 4.9% (58/1176), and ceftriaxone resistance was 0% (0/1176). Cefixime resistance was highest among women (16.4%, 10/61), followed by men who have sex with women (6.4%, 7/109) and men who have sex with men (5.8%, 57/982). The prevalence of cefixime-resistant N gonorrhoeae exceeds the threshold of the 5% resistance level recommended by the World Health Organization; thus, cefixime treatment would have limited benefits in Australia.

Original language	English
Pages (from-to)	e1121-e1125
Journal	Journal of Infectious Diseases
Volume	230
Issue number	5
DOIs	https://doi.org/10.1093/infdis/jiae313
Publication status	Published - 15 Nov 2024
Externally published	Yes

Bibliographical note

Publisher Copyright:
© 2024 The Author(s).

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Neisseria gonorrhoeae
antimicrobial resistance
gonorrhea
resistance
treatment

Access to Document

10.1093/infdis/jiae313

Cite this

Chow, E. P. F., Stevens, K., De Petra, V., Chen, M. Y., Bradshaw, C. S., Sherry, N. L., Barbee, L. A., Vodstrcil, L. A., Aguirre, I., Seib, K. L., Maddaford, K., Williamson, D. A., Howden, B. P., & Fairley, C. K. (2024). Prevalence of Cefixime-Resistant Neisseria gonorrhoeae in Melbourne, Australia, 2021-2022. Journal of Infectious Diseases, 230(5), e1121-e1125. https://doi.org/10.1093/infdis/jiae313

@article{477f8947e5b5488daaa68f438e1bb115,

title = "Prevalence of Cefixime-Resistant Neisseria gonorrhoeae in Melbourne, Australia, 2021-2022",

abstract = "While ceftriaxone remains the first-line treatment for gonorrhea, the US Centers for Disease Control and Prevention recommended cefixime as a second-line treatment in 2021. We tested 1176 Neisseria gonorrhoeae isolates among clients attending the Melbourne Sexual Health Centre in 2021 and 2022. The prevalence of cefixime resistance was 6.3\% (74/1176), azithromycin resistance was 4.9\% (58/1176), and ceftriaxone resistance was 0\% (0/1176). Cefixime resistance was highest among women (16.4\%, 10/61), followed by men who have sex with women (6.4\%, 7/109) and men who have sex with men (5.8\%, 57/982). The prevalence of cefixime-resistant N gonorrhoeae exceeds the threshold of the 5\% resistance level recommended by the World Health Organization; thus, cefixime treatment would have limited benefits in Australia.",

keywords = "Neisseria gonorrhoeae, antimicrobial resistance, gonorrhea, resistance, treatment",

author = "Chow, \{Eric P.F.\} and Kerrie Stevens and \{De Petra\}, Vesna and Chen, \{Marcus Y.\} and Bradshaw, \{Catriona S.\} and Sherry, \{Norelle L.\} and Barbee, \{Lindley A.\} and Vodstrcil, \{Lenka A.\} and Ivette Aguirre and Seib, \{Kate L.\} and Kate Maddaford and Williamson, \{Deborah A.\} and Howden, \{Benjamin P.\} and Fairley, \{Christopher K.\}",

note = "Publisher Copyright: {\textcopyright} 2024 The Author(s).",

year = "2024",

month = nov,

day = "15",

doi = "10.1093/infdis/jiae313",

language = "English",

volume = "230",

pages = "e1121--e1125",

journal = "Journal of Infectious Diseases",

issn = "0022-1899",

number = "5",

}

Chow, EPF, Stevens, K, De Petra, V, Chen, MY, Bradshaw, CS, Sherry, NL, Barbee, LA, Vodstrcil, LA, Aguirre, I, Seib, KL, Maddaford, K, Williamson, DA, Howden, BP & Fairley, CK 2024, 'Prevalence of Cefixime-Resistant Neisseria gonorrhoeae in Melbourne, Australia, 2021-2022', Journal of Infectious Diseases, vol. 230, no. 5, pp. e1121-e1125. https://doi.org/10.1093/infdis/jiae313

TY - JOUR

T1 - Prevalence of Cefixime-Resistant Neisseria gonorrhoeae in Melbourne, Australia, 2021-2022

AU - Chow, Eric P.F.

AU - Stevens, Kerrie

AU - De Petra, Vesna

AU - Chen, Marcus Y.

AU - Bradshaw, Catriona S.

AU - Sherry, Norelle L.

AU - Barbee, Lindley A.

AU - Vodstrcil, Lenka A.

AU - Aguirre, Ivette

AU - Seib, Kate L.

AU - Maddaford, Kate

AU - Williamson, Deborah A.

AU - Howden, Benjamin P.

AU - Fairley, Christopher K.

PY - 2024/11/15

Y1 - 2024/11/15

N2 - While ceftriaxone remains the first-line treatment for gonorrhea, the US Centers for Disease Control and Prevention recommended cefixime as a second-line treatment in 2021. We tested 1176 Neisseria gonorrhoeae isolates among clients attending the Melbourne Sexual Health Centre in 2021 and 2022. The prevalence of cefixime resistance was 6.3% (74/1176), azithromycin resistance was 4.9% (58/1176), and ceftriaxone resistance was 0% (0/1176). Cefixime resistance was highest among women (16.4%, 10/61), followed by men who have sex with women (6.4%, 7/109) and men who have sex with men (5.8%, 57/982). The prevalence of cefixime-resistant N gonorrhoeae exceeds the threshold of the 5% resistance level recommended by the World Health Organization; thus, cefixime treatment would have limited benefits in Australia.

AB - While ceftriaxone remains the first-line treatment for gonorrhea, the US Centers for Disease Control and Prevention recommended cefixime as a second-line treatment in 2021. We tested 1176 Neisseria gonorrhoeae isolates among clients attending the Melbourne Sexual Health Centre in 2021 and 2022. The prevalence of cefixime resistance was 6.3% (74/1176), azithromycin resistance was 4.9% (58/1176), and ceftriaxone resistance was 0% (0/1176). Cefixime resistance was highest among women (16.4%, 10/61), followed by men who have sex with women (6.4%, 7/109) and men who have sex with men (5.8%, 57/982). The prevalence of cefixime-resistant N gonorrhoeae exceeds the threshold of the 5% resistance level recommended by the World Health Organization; thus, cefixime treatment would have limited benefits in Australia.

KW - Neisseria gonorrhoeae

KW - antimicrobial resistance

KW - gonorrhea

KW - resistance

KW - treatment

UR - https://www.scopus.com/pages/publications/85209752124

U2 - 10.1093/infdis/jiae313

DO - 10.1093/infdis/jiae313

M3 - Article

C2 - 38877763

AN - SCOPUS:85209752124

SN - 0022-1899

VL - 230

SP - e1121-e1125

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

IS - 5

ER -

Prevalence of Cefixime-Resistant Neisseria gonorrhoeae in Melbourne, Australia, 2021-2022

Abstract

Bibliographical note

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this